The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

Clinical Pharmacology and Therapeutics
K FattingerP J Meier

Abstract

During clinical trials bosentan, the first orally active endothelin receptor antagonist, caused asymptomatic transaminase elevations in some patients. In this study we investigated whether inhibition of the hepatocanalicular bile salt export pump (rodents, Bsep; humans, BSEP ABCB11) could account for bosentan-induced liver injury. We reanalyzed the safety database of the bosentan trials for cholestatic liver injury, determined the cholestatic potency of bosentan in the rat, and studied the effects of bosentan and its metabolites on Bsep-mediated taurocholate transport in vitro. Bosentan caused dose-dependent and reversible liver injury in 2% to 18% of patients and caused a significant increase of serum bile salt levels (P <.01). Concomitant administration of glyburide (INN, glibenclamide) enhanced the cholestatic potency of bosentan. Similar effects were seen in rats, in which serum bile salt levels were increased by glyburide less than by bosentan, which increased the levels less than a combination of bosentan and glyburide. In vitro, Bsep-mediated taurocholate transport was inhibited by bosentan (inhibition constant, approximately 12 micromol/L) and metabolites (inhibition constant, approximately 8.5 micromol/L for metabolite...Continue Reading

Citations

May 5, 2011·European Journal of Clinical Pharmacology·Patricia N SidhartaJasper Dingemanse
Jun 6, 2006·Molecular Pharmaceutics·Giulia GhibelliniKim L R Brouwer
Jul 26, 2002·The New England Journal of Medicine·Brett N Pereira, Sundeep Salvi
Feb 12, 2010·Toxicological Sciences : an Official Journal of the Society of Toxicology·Katalin JemnitzLászló Vereczkey
Sep 11, 2010·Toxicological Sciences : an Official Journal of the Society of Toxicology·Ryan E MorganHisham K Hamadeh
Aug 21, 2013·Toxicological Sciences : an Official Journal of the Society of Toxicology·Ryan E MorganHisham K Hamadeh
Aug 16, 2013·Toxicological Sciences : an Official Journal of the Society of Toxicology·Mathieu VinkenVera Rogiers
Nov 7, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Shringi SharmaStephen C Strom
May 1, 2010·The Journal of Pharmacology and Experimental Therapeutics·Jin Kyung LeeKim L R Brouwer
Nov 13, 2012·The Journal of Pharmacology and Experimental Therapeutics·Toshihiko NishimuraGary Peltz
Apr 6, 2007·Biological & Pharmaceutical Bulletin·Takashi IwanagaIkumi Tamai
Jan 27, 2005·Circulation Journal : Official Journal of the Japanese Circulation Society·Shigetake SasayamaSatoshi Tanaka
May 1, 2005·Future Cardiology·Steeve ProvencherOlivier Sitbon
Nov 19, 2009·Drug Design, Development and Therapy·Kari E Roberts, Ioana R Preston
Oct 21, 2009·World Journal of Gastroenterology : WJG·Ignazio GrattaglianoPiero Portincasa
Jul 1, 2005·Future Cardiology·Lewis J RubinMichael J Gerber
Oct 29, 2013·Annual Review of Pharmacology and Toxicology·Nathan D PfeiferKim L R Brouwer
Nov 15, 2014·Archives of Toxicology·Paul JenningsJeffrey S Wiseman
Nov 19, 2014·Global Cardiology Science & Practice·Karim Said
Jul 4, 2003·Canadian Journal of Physiology and Pharmacology·Nicolas Bousette, Adel Giaid
Apr 23, 2013·Trends in Pharmacological Sciences·Gary Peltz
Jul 8, 2014·Expert Review of Respiratory Medicine·Hilary M DuBrock, Richard N Channick
Aug 21, 2015·Expert Opinion on Pharmacotherapy·Swanny PerrinOlivier Sitbon
Jun 10, 2009·Expert Review of Cardiovascular Therapy·Benjamin J Epstein, Shawn Anderson
Dec 24, 2009·Drug Metabolism Reviews·Bruno Stieger
Mar 5, 2014·Expert Opinion on Drug Metabolism & Toxicology·Manuela de Lima Toccafondo Vieira, Carlos Alberto Tagliati
Sep 28, 2014·Expert Opinion on Drug Metabolism & Toxicology·Christoph G Dietrich, Andreas Geier
Feb 2, 2013·Drug Metabolism Reviews·Eva RamboerMathieu Vinken
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Robert Naeije, Sandrine Huez
Apr 7, 2010·Expert Opinion on Drug Metabolism & Toxicology·Shibashish GiriAugustinus Bader
Apr 25, 2008·Expert Opinion on Drug Metabolism & Toxicology·Christoph Funk
Jan 5, 2002·Expert Opinion on Investigational Drugs·P Moreau, H H Dao
Jul 12, 2008·Expert Opinion on Investigational Drugs·Frank EnseleitFrank Ruschitzka
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Jasminder Sahi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.